Rivaroxaban Hypericum Trial

Inclusion Criteria: * Men or women, age between 18 and 45 years (inclusive) at screening * BMI between 18 and 28 kg/m2 (inclusive) at screening * No clinically significant findings on the physical examination at screening * Hematology and clinical chemistry results not deviating from the normal range to a clinically relevant extent at screening * Ability to communicate well with the investigator and to understand and comply with the requirements of the study * Women of child-bearing age: willingness of using a double barrier contraception method during the study, i.e. a hormonal method (oral contraceptive, intrauterine device) in combination with a mechanical barrier (e.g. condom, diaphragm) * Signed informed consent Exclusion Criteria: * Known allergic reaction to any excipient of the drug formulations * Known photosensitivity * Smoking * History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening * Loss of ≥ 250 ml of blood within 3 months prior to screening, including blood donation * Treatment with an investigational drug within 30 days prior to screening * Previous treatment with any prescribed or over-the-counter medications (including herbal medicines such as St. John's wort) within 2 weeks prior to screening * Pregnant (positive results from urine drug screen at screening) or lactating women * History or clinical evidence of any disease (e.g. gastrointestinal tract disease) and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drugs, or which might increase the risk for toxicity * Legal incapacity or limited legal capacity at screening * Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol